PharmaKure Company
PharmaKure is a drug discovery company that develops a drug candidate for Alzheimer's disease treatment. PharmaKure already owns intellectual property on one drug discovered by its screening approach. The company's strategy is to find new uses for known compounds or drugs through our phenotypic screening methods. PharmaKure is a clinical-stage drug platform company. Its objective is to accelerate the development of therapies addressing neurodegeneration disease caused by protein misfolding/protein aggregation, such as Alzheimer's disease (AD), Parkinson's disease (PD) and rare disease Gerstmann-Straussler Scheinker (GSS) through the use of 're-purposing of previously approved drugs. PharmaKure's proprietary SSV technology (Screen-Select-Validate) is the engine to search for and develop new therapies from approved drugs to build out the pipeline, patent them, and then take them into fast-track clinical trials.
Industry:
NeuroTech
Headquarters:
Manchester, United Kingdom
Founded Date:
2019
Employees Number:
11-50
Funding Status:
Early Stage VC
Estimated Revenue:
£780 000-£7 800 000
Last Funding Date:
09-16-2020
Register and Claim Ownership